Skip to main content


Development of a serocorrelate of protection against invasive Group B Streptococcus disease (iGBS)


Medical Research Council & MinervaX

Type of Study

Case control study


St George’s, University of London


United Kingdom

Chief Investigator

Professor Paul Heath


Pregnant women and babies infected with invasive GBS under 90 days of age


A vaccine against Group B Streptococcus has been developed and is currently being tested. If effective this could be offered to pregnant women to protect their babies from this devastating disease. However, we do not know what level of antibody is needed to protect infants against GBS. We need to collect comprehensive information about the amount of antibody that protects infants from GBS in order to facilitate the development and licensure of a vaccine to give to pregnant women.

This is a multicentre study to provide evidence that the relationship between an immune marker value (anti-GBS IgG concentration) and the probability of invasive GBS (iGBS) disease in infants less than 3 months of age is sufficiently strong that a vaccine able to induce an immune response will lead to a meaningful decrease in the probability of iGBS disease.


August 2020 – March 2024